Multidomain cardiometabolic burden separated risk inside adapted CKM stages
A composite score built from C-reactive protein, lipid accumulation product, and pulse pressure tracked incident cardiovascular disease across a large community cohort, even after adjustment for established risk factors. In practical terms, the signal did not come from one pathway alone. It came from the convergence of inflammation, visceral lipid burden, and pulsatile arterial load — three biologically distinct processes that often travel together but are rarely measured as a single burden at the bedside.
The analysis drew on 7779 adults aged 45 years or older from CHARLS, all free of cardiovascular disease at baseline. Over a median follow-up of 9.0 years, 1911 cardiovascular events accrued. Each 1-SD increase in the combined inflammatory, lipid-accumulation, and pulsatile hemodynamic measure, abbreviated CLP, was associated with a higher hazard of cardiovascular disease after multivariable adjustment, with a hazard ratio of 1.22 and a 95% confidence interval of 1.16 to 1.28. The highest quartile carried substantially greater risk than the lowest, with a hazard ratio of 1.85.
The gradient was not subtle. Nine-year cumulative incidence rose from 13.9% in the lowest quartile to 27.8% in the highest.
Why inflammation, visceral fat, and pulse pressure belong in the same conversation
Each component of CLP captures a different layer of vascular injury. CRP reflects systemic inflammatory activity, which can destabilize endothelium and accelerate atherosclerotic plaque development. LAP estimates lipid overaccumulation and central adiposity, a phenotype tied to insulin resistance, dyslipidemia, and pro-atherogenic metabolic signaling. Pulse pressure rises when large-artery stiffness increases, turning each systolic contraction into a more damaging hemodynamic stressor for the arterial wall.
A combined score makes biological sense because these pathways reinforce one another. Inflammation and visceral fat promote endothelial dysfunction; arterial stiffness then magnifies mechanical injury across the vascular tree. The result is not just a higher average risk, but a broader spread of risk among people who may otherwise sit in the same nominal risk stratum.
That spread is exactly what the cohort exposed inside adapted CKM stages. Within adapted stage 2, nine-year cumulative incidence ranged from 16.2% to 29.8%, showing that stage labels alone can blur substantial heterogeneity in absolute risk. Relative associations did not differ significantly across stages, with a P value for interaction of 0.147, which suggests the CLP signal persisted across stages rather than concentrating in just one category.
What the cohort design can and cannot tell clinicians
This was a prospective analysis with long follow-up, and the result set was internally consistent across several analytic approaches. Associations remained robust in competing-risk analyses, selection-weighted analyses, and alternative event-time models. Those sensitivity checks matter because they make the central finding harder to dismiss as an artifact of one statistical framework.
Still, epidemiology has boundaries. The score is not a treatment target, and it is not yet a clinical instrument for routine decision-making. The investigators framed CLP as an epidemiologic characterization of multidomain burden, not a validated bedside score. External validation remains necessary before the measure could be considered for clinical use.
The value of the finding lies in risk architecture. Conventional staging systems organize patients by broad disease progression, but broad stages can hide people with strikingly different vascular biology. A patient with modestly elevated inflammation, central lipid accumulation, and widened pulse pressure may carry more risk than stage assignment alone suggests, even if no single measurement appears extreme.
Absolute risk moved more than the labels did
The most clinically meaningful observation is the widening of absolute risk. A relative hazard ratio is useful, but absolute incidence shapes prevention decisions, counseling, and the urgency of intervention. When risk climbs from 13.9% to 27.8% across quartiles over nine years, the burden is not theoretical. It translates into more events in real communities, more opportunity for prevention, and more need to recognize clustered biology early.
Within adapted stage 2, the same pattern persisted. Stage membership did not flatten the curve; it only partially described it. The score captured continuous multidomain burden inside a staging system that otherwise groups patients into discrete bins. In vascular medicine, that distinction matters because atherosclerotic disease rarely advances in discrete jumps. It accumulates through overlapping inflammatory, metabolic, and hemodynamic stress.
A biomarker composite that fits the pathophysiology of vascular aging
The choice of CRP, LAP, and pulse pressure aligns with the pathophysiology of vascular aging and cardiometabolic injury. CRP supplies a readout of inflammatory tone. LAP reflects central adiposity and lipid overload, both of which are closely tied to insulin resistance and adverse lipoprotein patterns. Pulse pressure acts as a surrogate for arterial stiffness, which increases with age, hypertension, and cumulative vascular damage.
Measured together, these variables may be more informative than any single component because they map onto different stages of injury. One variable captures the inflammatory milieu, another the metabolic substrate, and another the mechanical consequence. A patient can look only moderately abnormal on one axis and still sit in a high-risk zone when the three are combined.
The study’s equal-weight composite is also notable. By standardizing and summing the three components, the score treated them as complementary contributors rather than competing explanations. Whether another weighting scheme would perform better remains unproven, but the current approach offers a clean epidemiologic model for multidomain risk burden.
External validation will determine whether this becomes more than a research score
The cohort findings support the idea that a composite inflammatory-metabolic-hemodynamic burden can sharpen cardiovascular risk assessment inside adapted CKM stages. The result is useful because it suggests that stage-based frameworks may be strengthened by biologic layering rather than replaced by it.
No immediate clinical implementation follows from this paper alone. The cohort was drawn from CHARLS, the analysis was observational, and the authors explicitly called for external validation before clinical use. The next step is not to rush the score into practice, but to see whether it reproduces in other populations, whether it predicts events as well in different age structures and healthcare settings, and whether it adds enough discrimination beyond standard risk tools to justify adoption.
For now, the practical takeaway is narrower and more defensible: cardiovascular risk inside adapted CKM stages is not uniform, and a combined inflammatory, lipid-accumulation, and pulsatile hemodynamic burden can expose the variation that staging alone leaves hidden. The unanswered question is whether this biologic layering improves prevention decisions enough to change care, or remains best used as a research framework for characterizing risk.